Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)

Inclusion Criteria: * Chronic venous insufficiency stage I or II according to Widmer, e.g., resulting in lower-leg oedema * Male or female out-patients of any ethnic origin * Age ranging from 25 to 75 years Exclusion Criteria: * Known hypersensitivity to any ingredients of the study medication * Oedema(s) of non-venous origin, e.g., due to cardiac insufficiency, lymphoedema or decompensated cardiac insufficiency, orthopaedic disturbances * Florid venous ulcers * Arterial occlusive disease, irrespective of the severity * Phlebitis or thrombophlebitis * Clinical indication for an acute phlebologic intervention, e.g., compressive treatment, phlebectomy, etc. * Evidence of diabetic micro-angiopathy or polyneuropathy in medical history * Poor general health (based on the investigator's judgement) * Addiction to alcohol abuse * Mental illness and inability (or limited ability) to work, or inability (or limited ability) to follow spoken or written explanations concerning the trial * Women of child-bearing age not using any reliable contraceptive methods * Pregnant or lactating women * Patients previously enrolled in the present study or participating in another clinical study, or who had taken part in another study within the previous 90 days * Patients receiving compression therapy, high-ceiling diuretics (e.g., furosemide), or any other anti-CVI preparations (e.g., vasoprotectives to treat varicosis, such as heparin-containing preparations, sclerosing agents, or bioflavonoids o…